Business Context and Reporting Period
This Form 8-K Current Report was filed by Indivior Pharmaceuticals, Inc. on May 4, 2026. The filing discloses a material corporate action regarding the company's capital allocation strategy, specifically the execution of an accelerated share repurchase agreement.
Key Financial Metrics and Transaction Details
- Transaction Type: Accelerated Share Repurchase (ASR) Agreement.
- Prepayment Amount: $175.0 million.
- Initial Shares Received: 3,717,473 shares of common stock.
- Program Context: This transaction is part of a previously announced $400 million share repurchase program.
- Expected Settlement Date: June 22, 2026.
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period, as this is a current report focused on a specific event rather than a periodic financial statement.
Material Changes and Transaction Mechanics
The Company entered into an agreement with an investment bank counterparty to repurchase shares. The total number of shares to be repurchased will be determined based on the average of the daily volume-weighted average prices (VWAP) of the shares during the term of the transaction, less a discount. Upon final settlement, the Company may receive additional shares or, under certain circumstances, may be required to deliver shares or make a cash payment to the counterparty.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard terms of the ASR agreement. The primary contingency noted is the final settlement calculation, which depends on future stock price performance during the transaction term.
Investor Verification Checklist
- Verify the remaining balance of the $400 million share repurchase program after this $175.0 million commitment.
- Monitor the final settlement date (June 22, 2026) to determine the total number of shares repurchased and the final average price.
- Review the full text of the press release (Exhibit 99.1) for any additional details on the counterparty or specific discount terms.
- Confirm the impact of the $175.0 million cash outflow on the company's current liquidity position via the most recent 10-Q or 10-K.